Bleiziffer S, Krane M, Deutsch M A, Elhmidi Y, Piazza N, Voss B, Lange R
Clinic for Cardiovascular Surgery, German Heart Center Munich, Lazarettstr. 36, 80636 Munich, Germany.
Curr Cardiol Rev. 2013 Nov;9(4):268-73. doi: 10.2174/1573403x09666131202123326.
TAVI (transcatheter aortic valve implantation) is a less invasive treatment of the stenotic aortic valve while avoiding midline sternotomy and cardiopulmonary bypass. A crimped biological valve on a self-expanding or balloonexpandable stent is inserted antegradely or retrogradely under fluoroscopy, and deployed on the beating heart. Among the worldwide TAVI programs, many different concepts have been established for the choice of the access site. Whether retrograde or antegrade TAVI should be considered the superior approach is matter of an ongoing debate. The published literature demonstrates safety of all techniques if performed within a dedicated multidisciplinary team. Since there is no data providing evidence if one approach is superior to another, we conclude that an individualized patient-centered decision making process is most beneficial, taking advantage of the complementarity of the different access options. The aim of this article is to give an overview of the current practice of access techniques for transcatheter based valve treatment and to outline the respective special characteristics.
经导管主动脉瓣植入术(TAVI)是一种治疗主动脉瓣狭窄的侵入性较小的方法,可避免正中开胸和体外循环。在透视引导下,将卷曲在自膨胀或球囊扩张支架上的生物瓣膜顺行或逆行插入,并在跳动的心脏上展开。在全球范围内的TAVI项目中,对于入路部位的选择已经确立了许多不同的概念。逆行还是顺行TAVI应被视为更优方法,这仍是一个持续争论的问题。已发表的文献表明,如果在专业的多学科团队中进行,所有技术都是安全的。由于没有数据证明一种方法优于另一种方法,我们得出结论,以患者为中心的个体化决策过程最为有益,利用不同入路选择的互补性。本文的目的是概述基于导管的瓣膜治疗入路技术的当前实践,并概述各自的特殊特征。